Arcus Biosciences, Inc.
RCUS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $238 | $248 | $192 | $150 |
| Short-Term Investments | $593 | $663 | $805 | $828 |
| Receivables | $14 | $20 | $21 | $25 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $12 | $15 | $13 | $13 |
| Total Curr. Assets | $857 | $946 | $1,031 | $1,016 |
| Property Plant & Equip (Net) | $42 | $44 | $46 | $47 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $10 | $16 | $8 | $14 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $65 | $69 | $71 | $73 |
| Total NC Assets | $117 | $129 | $125 | $134 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $974 | $1,075 | $1,156 | $1,150 |
| Liabilities | – | – | – | – |
| Payables | $42 | $29 | $22 | $18 |
| Short-Term Debt | $13 | $12 | $12 | $12 |
| Tax Payable | $0 | $0 | $0 | $1 |
| Deferred Revenue | $52 | $71 | $72 | $85 |
| Other Curr. Liab. | $128 | $98 | $86 | $110 |
| Total Curr. Liab. | $235 | $210 | $192 | $226 |
| LT Debt | $98 | $97 | $48 | $48 |
| Deferred Rev, NC | $53 | $60 | $219 | $234 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $152 | $159 | $166 | $157 |
| Total NC Liab. | $303 | $316 | $433 | $439 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $13 | $12 | $12 | $12 |
| Total Liabilities | $538 | $526 | $625 | $665 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $1,815 | $1,793 | $1,775 | $1,617 |
| Retained Earnings | -$1,379 | -$1,244 | -$1,244 | -$1,132 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $0 | $0 | $0 | $0 |
| Total Equity | $436 | $549 | $531 | $485 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $974 | $1,075 | $1,156 | $1,150 |
| Net Debt | -$127 | -$139 | -$132 | -$90 |